PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23349014-7 2013 Treatment with low-dose aspirin to mice homozygous for the TH-MYCN transgene significantly reduced the tumor burden (P < 0.01), the presence of tumor-associated cells of the innate immune system (P < 0.01), as well as the intratumoral expression of transforming growth factor-beta, thromboxane A2 (P < 0.05) and prostaglandin D2 (P < 0.01). Aspirin 24-31 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 62-66 23349014-8 2013 In conclusion, tumor-associated inflammation appears as a potential therapeutic target in NB and low-dose aspirin reduces tumor burden in the TH-MYCN transgenic mouse model of NB, hence warranting further studies on aspirin in high-risk NB. Aspirin 106-113 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 145-149 24073359-2 2013 The continuous administration of low-dose aspirin to TH-MYCN mice (a model of pediatric neuroblastoma) delays tumor outgrowth and decreases tumor-promoting inflammation by inhibiting regulatory cells of the innate immune system as well as immunosuppressive mediators such as transforming growth factor beta (TGFbeta) and thromboxane A2. Aspirin 42-49 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 56-60